Kronos Bio, Inc.

NasdaqGS:KRON 株式レポート

時価総額:US$60.7m

このページの翻訳は実験的なもので、現在開発中です。お待ちしております!

Kronos Bio マネジメント

マネジメント 基準チェック /34

Kronos Bio'sの CEO はNorbert Bischofbergerで、 Aug2018年に任命され、 の在任期間は 5.83年です。 の年間総報酬は$ 1.76Mで、 32.9%給与と67.1%のボーナス(会社の株式とオプションを含む)で構成されています。 は、会社の株式の17.93%を直接所有しており、その価値は$ 10.88M 。経営陣と取締役会の平均在任期間はそれぞれ2.3年と5年です。

主要情報

Norbert Bischofberger

最高経営責任者

US$1.8m

報酬総額

CEO給与比率32.9%
CEO在任期間5.8yrs
CEOの所有権17.9%
経営陣の平均在職期間2.3yrs
取締役会の平均在任期間5yrs

経営陣の近況

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Recent updates

Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Jun 20
Shareholders Will Probably Hold Off On Increasing Kronos Bio, Inc.'s (NASDAQ:KRON) CEO Compensation For The Time Being

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Jun 11
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio: Still Promising But Riskier Following ASCO Update

Jun 05

Kronos Bio: Underestimated Drug Discovery Platform

May 06

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jan 19
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

Aug 21
We're Keeping An Eye On Kronos Bio's (NASDAQ:KRON) Cash Burn Rate

We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Feb 22
We Think Kronos Bio (NASDAQ:KRON) Needs To Drive Business Growth Carefully

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Nov 01
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Deliver On Growth Plans?

Kronos Bio, Invivoscribe to develop companion diagnostic for leukemia drug entospletinib

Aug 16

Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

Jul 07
Is Kronos Bio (NASDAQ:KRON) In A Good Position To Invest In Growth?

We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

Feb 01
We're Hopeful That Kronos Bio (NASDAQ:KRON) Will Use Its Cash Wisely

How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Mar 03
How Much Of Kronos Bio, Inc. (NASDAQ:KRON) Do Insiders Own?

Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Jan 09
Read This Before Selling Kronos Bio, Inc. (NASDAQ:KRON) Shares

Kronos Bio  EPS misses by $4.10

Nov 18

CEO報酬分析

Kronos Bio の収益と比較して、Norbert Bischofberger の報酬はどのように変化したか?
日付総報酬給与会社業績
Mar 31 2024n/an/a

-US$116m

Dec 31 2023US$2mUS$580k

-US$113m

Sep 30 2023n/an/a

-US$119m

Jun 30 2023n/an/a

-US$120m

Mar 31 2023n/an/a

-US$123m

Dec 31 2022US$3mUS$580k

-US$133m

Sep 30 2022n/an/a

-US$164m

Jun 30 2022n/an/a

-US$165m

Mar 31 2022n/an/a

-US$161m

Dec 31 2021US$645kUS$320k

-US$151m

Sep 30 2021n/an/a

-US$122m

Jun 30 2021n/an/a

-US$128m

Mar 31 2021n/an/a

-US$108m

Dec 31 2020US$15mUS$399k

-US$88m

Sep 30 2020n/an/a

-US$61m

Jun 30 2020n/an/a

-US$25m

Mar 31 2020n/an/a

-US$20m

Dec 31 2019US$280kUS$200k

-US$16m

報酬と市場: Norbertの 総報酬 ($USD 1.76M ) は、 US市場 ($USD 678.50K ) の同規模の企業の平均を上回っています。

報酬と収益: Norbertの報酬は、過去 1 年間の会社の業績と一致しています。


CEO(最高経営責任者

Norbert Bischofberger (68 yo)

5.8yrs

在職期間

US$1,761,537

報酬

Dr. Norbert W. Bischofberger, Ph D., is Independent Director of Vir Biotechnology, Inc. from May 29, 2024. He has been an Independent Director of Morphic Holding, Inc. since June 14, 2019.Dr. Bischofberge...


リーダーシップ・チーム

名称ポジション在職期間報酬所有権
Norbert Bischofberger
President5.8yrsUS$1.76m17.93%
$ 10.9m
Joshua Kazam
Co-Founder & Directorno dataUS$74.80k0.61%
$ 370.2k
David Tanen
Secretary & Directorno dataUS$74.80k1.52%
$ 922.9k
Deborah Knobelman
COO & CFOno dataデータなし0.27%
$ 165.9k
Margaux Bennett
Vice President of Corporate Development & Investor Relations3.1yrsデータなしデータなし
Allison Frisbee
Senior Vice President of Corporate Operations & Legalless than a yearデータなし0.34%
$ 206.6k
Charles Lin
Senior Vice President of Research & Development3.4yrsデータなし0.39%
$ 236.9k
Elizabeth Olek
Senior Vice President of Clinical Development2.3yrsデータなし0.32%
$ 195.2k
Wes Trotter
Senior Vice President of Drug Discovery & Pharmaceutical Development1.2yrsデータなしデータなし

2.3yrs

平均在職期間

50yo

平均年齢

経験豊富な経営陣: KRONの経営陣は 経験豊富 であると考えられます ( 2.3年の平均在職年数)。


取締役

名称ポジション在職期間報酬所有権
Norbert Bischofberger
President6.2yrsUS$1.76m17.93%
$ 10.9m
Joshua Kazam
Co-Founder & Director7yrsUS$74.80k0.61%
$ 370.2k
David Tanen
Secretary & Director7yrsUS$74.80k1.52%
$ 922.9k
Owen Witte
Scientific Advisory Board Chairmanno dataデータなしデータなし
Arie Belldegrun
Independent Chairman of the Board6.6yrsUS$117.20k1.13%
$ 686.4k
Elena Ridloff
Independent Director3.8yrsUS$89.17k0.0044%
$ 2.7k
Taiyin Yang
Independent Director3.3yrsUS$88.70k0.019%
$ 11.4k
Roshawn Blunt
Independent Director2.6yrsUS$79.80k0%
$ 0
Angela Koehler
Scientific Advisory Board Memberno dataデータなしデータなし
Robert Eisenman
Scientific Advisory Board Memberno dataデータなしデータなし
Myles Brown
Scientific Advisory Board Memberno dataデータなしデータなし
Katherine Stultz
Independent Director1.3yrsUS$105.68k0%
$ 0

5.0yrs

平均在職期間

53yo

平均年齢

経験豊富なボード: KRONの 取締役会経験豊富 であると考えられます ( 5年の平均在任期間)。